(Legal Newsline) — California Attorney General Xavier Becerra announced March 1
that the state has joined a federal antitrust lawsuit with 39 other states
against six generic drugmakers. The lawsuit alleges the defendants
conspired to divide customers and markets as well as increase prices for two
“All consumers deserve fair and reasonable drug prices,” Becerra said. “[This] lawsuit represents one small step in what will be a
robust and sustained challenge to anticompetitive practices in the
pharmaceutical industry. My office is
committed to combating wrongful drug company conduct on behalf of all consumers
defendants in the case are Heritage Pharmaceuticals Inc., Aurobindo Pharma USA
Inc., Citron Pharma LLC, Mayne Pharma (USA) Inc., Mylan Pharmaceuticals Inc.
and Teva Pharmaceuticals USA Inc.
According to allegations, these companies
allocated markets among themselves for doxycycline hyclate delayed release, an
antibiotic, and glyburide, an oral diabetes medication. Each company
purportedly agreed to sell only in their allocated market. Additionally, the
defendants allegedly fixed prices of the drugs. According to the lawsuit, these
actions – planned through meetings at industry trade shows, customer
conferences and other events, as well as through direct email and phone
messages – constitute illegal anticompetitive acts.